A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...
Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...
Switzerland-based Novartis has developed a new anti-malaria drug, GanLum, that showed 97% effectiveness in late-stage trials.
Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with ...
NEW YORK — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
This was already my favorite kitchen knife, but thanks to this substantial refresh, it's more appealing than ever.
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
News Medical on MSN
Single-dose malaria treatment using four drugs achieves high cure rates in clinical trial
Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...
Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...
Indian Defence Review on MSN
New Malaria Treatment Could Save Hundreds of Thousands of Lives
A promising new malaria drug shows incredible promise in fighting resistance and could save thousands of lives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback